Novartis Acquires Cadent Therapeutics

Novacap Acquires Cadent, LLC

August 9, 2023

Media & Entertainment

Novacap has acquired Cadent, LLC, a New York–based provider of converged TV advertising platform solutions, from funds managed by Lee Equity Partners. The transaction will see Novacap partner with Cadent’s management to accelerate growth and expand the company’s converged TV and audience-targeting capabilities across CTV, traditional TV and digital inventory.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Cadent Acquires AdTheorent

June 21, 2024

Marketing & Advertising

Cadent, a portfolio company of private equity firm Novacap, acquired AdTheorent Holding Company, Inc. for $3.21 per share in an all-cash transaction valuing AdTheorent at approximately $324 million. The deal (announced April 1, 2024 and closed June 21, 2024) brings AdTheorent's machine-learning–driven programmatic advertising capabilities into Cadent's converged TV and omnichannel advertising platform to create an expanded audience activation offering.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.